08 Dec OHMX.bio and Fujirebio Europe Receive Grant of 720K EURO!
to Incorporate Third Generation Sequencing into Clinical In Vitro Diagnostics Platform.
Ghent, Belgium, December 8, 2020 – OHMX.bio, a provider of cutting-edge “omics” solutions, and Fujirebio Europe announced today that they have been awarded a 720K EURO research grant from Flanders Innovation & Entrepreneurship (VLAIO) to develop a clinical in vitro diagnostics (IVD) platform incorporating third generation sequencing (TGS) technologies. The project, called IVD-seq, will initially focus on a cost-efficient, accurate and portable IVD modular solution for highly polymorphic regions. The partners aim to expand the resulting platform solution to other molecular diagnostic markers.
The IVD-seq project brings together a unique and complementary partnership of clinical IVD expertise from Fujirebio Europe and third generation sequencing based-omics solutions from OHMX.bio to develop a best-in-class IVD solution that completely operates from Flanders, Belgium.
The aim of the research will be to create a TGS IVD platform by optimizing a multi-layer approach encompassing the initial sample and library preparation, state-of-the-art sequencing technologies and improved genotyping procedures. In addition, the project will strive toward multiplexing related clinical markers within one IVD solution and indexing this in a cost-efficient way over multiple different patient samples.
Fujirebio is a global leader in the field of high-quality IVD testing. It has more than 50 years’ accumulated experience in the conception, development, production and worldwide commercialization of robust IVD products.
OHMX.bio offers customers state-of-the-art solutions to their biological questions using cutting-edge “omics” technologies – transcriptomics, translatomics, proteomics and (epi)genetics. We provide start-to finish project management from sample preparation to customized data analysis and data reporting.
“Working on this project will illustrate the broad capabilities that OHMX.bio can provide to its partners and we very much look forward to combining our expertise with that of Fujirebio Europe, a true leader in diagnostics.”Prof. Gerben Menschaert, Chief Scientific Officer and co-founder of OHMX.bio
“We believe this research could take advantage of Third Generation Sequencing, resulting in better diagnostic information that can be utilized for the benefit of patients.”Christiaan De Wilde, Chief Executive Officer of Fujirebio Europe
This is an excerpt of the original press release that can be read here.
|Gerben Menschaert||Christiaan De Wilde|
|OHMX.bio +32 478 46 45 43 |
|Fujirebio Europe +32 9 329 17 03|